V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220022323 | 220007972 | 1.68 | null | null | 2017-10-29 | 2018-08-11 | Triple / Double Intrathecal Therapy | N | Y | 220030478 | TRIPLE INTRATHECAL |
| 220022324 | 220007984 | 1.86 | 88 | Curative (C) | 2015-03-04 | 2015-06-20 | FLAG | 02 | N | 220030497 | FLAG |
| 220022325 | 220014446 | 1.67 | 53.3 | Curative (C) | 2019-07-03 | 2020-03-10 | BOSUTINIB | N | N | 220030955 | BOSUTINIB |
| 220022326 | 220008241 | 1.5 | 53.7 | Curative (C) | 2015-11-01 | 2015-11-02 | UKALL14- Intens/CNS Proph | 2 | N | 220031302 | UKALL2014 |
| 220022327 | 220008268 | 1.86 | 84.1 | Disease modification (D) | 2018-11-09 | 2018-11-16 | Docetaxel | N | N | 220031415 | OXALIPLATIN + MDG |
| 220022328 | 220008477 | 1.82 | 56.5 | Disease modification (D) | 2015-02-24 | 2015-03-05 | Alemtuzumab cond (RI ALLO CAMP100) | N | N | 220032108 | ALEMTUZUMAB |
| 220022329 | 220021575 | 1.55 | 89 | Curative (C) | 2018-02-09 | 2018-02-09 | CARBOPLATIN + GEMCITABINE | Y | N | 220033250 | GEMCARBO |
| 220022330 | 220008962 | 1.62 | 57.8 | Curative (C) | 2018-10-28 | 2018-10-31 | FLA | N | N | 220033807 | WT1 TRIAL |
| 220022331 | 220009163 | 1.72 | 67.5 | Curative (C) | 2016-02-15 | 2016-02-17 | CLOFARABINE + DAUNORUBICIN | 02 | null | 220034495 | CISPLATIN + ETOPOSIDE |
| 220022332 | 220016749 | 1.72 | 83.8 | Curative (C) | 2017-05-20 | 2017-08-10 | Cytarabine High Dose | N | N | 220011747 | CYTARABINE HIGH DOSE |
| 220022333 | 220019316 | 1.8 | 0 | Disease modification (D) | 2017-12-18 | 2018-07-09 | Nilotinib | 02 | N | 220020158 | NILOTINIB |
| 220022334 | 220005222 | 1.84 | 78.7 | Curative (C) | 2018-09-01 | 2018-09-01 | AML 19 TRIAL | N | N | 220020435 | AML19 TRIAL |
| 220022336 | 220005355 | 0 | 7.2 | null | 2020-01-01 | 2020-03-09 | null | 2 | N | 220020673 | NOT MATCHED |
| 220022337 | 220005673 | null | 95.2 | Curative (C) | null | 2019-05-01 | AML18 PILOT TRIAL | Y | N | 220021572 | PILOT TRIAL |
| 220022338 | 220005763 | 1.76 | null | Curative (C) | 2018-04-04 | 2018-05-16 | Dasatinib | N | N | 220021789 | DASATINIB |
| 220022339 | 220014360 | null | 49.8 | Curative (C) | null | 2019-07-11 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | null | 220030435 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220022340 | 220014374 | 0 | 85.1 | Disease modification (D) | 2018-08-17 | 2018-08-19 | AML Int Guide ADE 10+3+5 (1) | 02 | N | 220030478 | ADE |
| 220022341 | 220007984 | null | 100.8 | Curative (C) | 2015-08-09 | 2015-08-19 | PACLITAXEL | 2 | Y | 220030497 | PACLITAXEL |
| 220022342 | 220008148 | 1.55 | 50.8 | Curative (C) | 2020-03-10 | 2020-03-10 | METHOTREXATE | 02 | N | 220030955 | FBC |
| 220022343 | 220008478 | 1.83 | 65.8 | Curative (C) | 2015-03-31 | 2015-03-31 | Trifluridine + Tipiracil | 1 | N | 220032108 | THALIDOMIDE |
| 220022344 | 220021575 | 1.73 | 95 | Curative (C) | 2018-03-24 | 2018-03-24 | LENALIDOMIDE | N | Y | 220033250 | SORAFENIB |
| 220022345 | 220008962 | 1.73 | null | Disease modification (D) | 2018-11-01 | 2018-11-02 | FIGARO TRIAL | N | N | 220033807 | UKALL60+ |
| 220022346 | 220009164 | 1.68 | null | Curative (C) | 2018-01-24 | 2018-03-02 | Arsenic trioxide | null | null | 220034495 | BORTEZOMIB + THALIDOMIDE |
| 220022347 | 220005088 | 0 | 0 | Curative (C) | 2018-02-20 | 2018-07-09 | Nilotinib | 02 | N | 220020158 | NILOTINIB |
| 220022348 | 220005356 | 1.77 | 71.8 | Curative (C) | 2020-04-18 | 2020-04-18 | AML 18 TRIAL | 1 | N | 220020673 | AML18 TRIAL |
| 220022349 | 220005673 | 1.77 | 75 | null | 2019-04-16 | 2019-09-10 | Methotrexate intrathecal | 2 | N | 220021572 | METHOTREXATE INTRATHECAL |
| 220022350 | 220014374 | 1.75 | 13.9 | Palliative (P) | 2016-11-22 | 2018-08-19 | ADE 8+3+5 | N | N | 220030478 | ADE |
| 220022351 | 220008148 | null | 62 | Curative (C) | null | 2020-05-01 | PONATINIB | 02 | N | 220030955 | CISPLATIN + GEMCITABINE |
| 220022352 | 220008962 | 1.74 | 94.2 | Disease modification (D) | 2019-01-21 | 2019-01-21 | MITOXANTRONE + TRETINOIN | 02 | N | 220033807 | IPILIMUMAB |
| 220022353 | 220009164 | 1.55 | null | Curative (C) | 2018-03-01 | 2018-03-02 | TIP | null | null | 220034495 | LENALIDOMIDE |
| 220022354 | 220005089 | 0 | 89 | Palliative (P) | 2017-11-07 | 2018-08-22 | Nilotinib | N | N | 220020158 | NILOTINIB |
| 220022355 | 220005356 | 0 | null | Curative (C) | 2020-01-04 | 2020-04-18 | Dasatinib | 02 | N | 220020673 | DASATINIB |
| 220022356 | 220019792 | 1.71 | 147 | null | 2018-06-06 | 2018-11-05 | Rituximab | N | N | 220030478 | RITUXIMAB |
| 220022357 | 220008148 | null | 65 | Adjuvant (A) | 2020-04-19 | 2020-05-02 | Methotrexate intrathecal | 2 | N | 220030955 | METHOTREXATE INTRATHECAL |
| 220022358 | 220019927 | 1.7 | 108.4 | Curative (C) | 2018-11-17 | 2018-11-18 | GEMTUZUMAB OZOGAMICIN | 02 | N | 220033807 | FBC |
| 220022359 | 220020916 | 1.7 | 95.6 | Not known (9) | null | 2018-11-05 | DA 3+8 | N | N | 220030478 | DA |
| 220022360 | 220008148 | 1.6 | 95.4 | Radical (R) | null | 2020-06-15 | Cytarabine High Dose | 2 | N | 220030955 | CYTARABINE HIGH DOSE |
| 220022361 | 220008963 | 1.63 | 63 | Curative (C) | 2018-10-02 | 2018-11-18 | Carboplatin + Paclitaxel (3 weekly) | N | N | 220033807 | CARBOPLATIN + PACLITAXEL |
| 220022362 | 220020916 | 1.7 | 77 | Curative (C) | 2018-12-23 | 2018-12-23 | DA 3 + 10 | null | N | 220030478 | DA |
| 220022363 | 220008964 | 1.69 | null | Curative (C) | 2019-01-29 | 2019-02-25 | Mitox + Tretinoin Spanish Course 3 | N | N | 220033807 | MITOXANTRONE |
| 220022364 | 220008965 | 1.73 | 61.35 | Curative (C) | 2019-04-23 | 2019-04-26 | CYCLOPHOSPHAMIDE | N | N | 220033807 | CYCLOPHOSPHAMIDE |
| 230000001 | 230000001 | null | null | Palliative (P) | 2013-06-30 | 2013-07-08 | Cisplatin + Docetaxel +Fluorouracil | N | N | 230006592 | OXALIPLATIN + RALTITREXED |
| 230000002 | 230000002 | 1.74 | 116.3 | Adjuvant (A) | 2016-07-06 | 2016-07-26 | CAPECITABINE + GEMCITABINE | 2 | N | 230014716 | OXALIPLATIN + MDG |
| 230000003 | 230000002 | 1.63 | 96 | Adjuvant (A) | 2016-04-19 | 2016-05-12 | FEC + TRASTUZUMAB | N | N | 230014716 | CARBOPLATIN + ETOPOSIDE |
| 230000004 | 230000002 | 1.72 | null | Adjuvant (A) | null | 2016-01-16 | Capecitabine + Cisplatin | null | N | 230014716 | OXALIPLATIN + MDG |
| 230000005 | 230000003 | 1.63 | 44 | Curative (C) | null | 2013-07-09 | CAPECITABINE + RT | Y | Y | 230014862 | CAPECITABINE |
| 230000006 | 230000003 | 1.61 | 47.5 | Palliative (P) | 2018-06-29 | 2018-06-29 | VANDETANIB | 02 | N | 230014862 | CAPECITABINE + RT |
| 230000007 | 230000004 | 1.6 | null | Curative (C) | 2014-06-03 | 2014-06-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | N | 230014902 | CAPECITABINE + RT |
| 230000008 | 230000004 | 0 | 62.8 | Curative (C) | 2015-07-27 | 2015-07-28 | AFATINIB | 02 | null | 230014902 | CAPECITABINE |
| 230000009 | 230000004 | 1.55 | 52.3 | Adjuvant (A) | 2015-06-29 | 2015-07-06 | Irinotecan + Modified De Gramont | Y | N | 230014902 | CAPECITABINE + OXALIPLATIN |